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Abstract: Neuroinflammation is one of the main contributors to the onset and progression
of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. Microglial and
astrocyte activation is a brain defense mechanism to counteract harmful pathogens and damaged
tissues, while their prolonged activation induces neuroinflammation that can trigger or exacerbate
neurodegeneration. Unfortunately, to date there are no pharmacological therapies able to slow
down or stop the progression of neurodegeneration. For this reason, research is turning to the
identification of natural compounds with protective action against these diseases. Considering the
important role of neuroinflammation in the onset and development of neurodegenerative pathologies,
natural compounds with anti-inflammatory activity could be good candidates for developing effective
therapeutic strategies. Marine organisms represent a huge source of natural compounds, and
among them, algae are appreciated sources of important bioactive components such as antioxidants,
proteins, vitamins, minerals, soluble dietary fibers, polyunsaturated fatty acids, polysaccharides,
sterols, carotenoids, tocopherols, terpenes, phycobilins, phycocolloids, and phycocyanins. Recently,
numerous anti-inflammatory compounds have been isolated from marine algae with potential
protective efficacy against neuroinflammation. This review highlights the key inflammatory processes
involved in neurodegeneration and the potential of specific compounds from marine algae to
counteract neuroinflammation in the CNS.
Keywords: neuroinflammation; neurodegeneration; algae; seaweeds; neurodegenerative diseases
1. Introduction
Neurodegeneration refers to a progressive and permanent loss of neurons in specified regions of
the brain and spinal cord. It is the pathological condition that characterizes many neurodegenerative
diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS),
Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) [1], and traumatic brain injury
(TBI) [2]. The main cellular and molecular events that trigger neurodegeneration are oxidative stress,
abnormal protein deposition, damaged mitochondrial function, induction of apoptosis, impairment of
proteostasis, and neuroinflammation [3]. Since the first identification of the main neurodegenerative
disorders, research on the molecular mechanisms underlying these pathologies has focused on major
anatomical changes such as neuronal loss and protein aggregation [4]. In recent years, more and
more studies have highlighted the key role of the immune system in the initiation and progression
of neurodegeneration [5,6] due to changes in cytokine signaling, immune cell proliferation and
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migration, altered phagocytosis, and reactive gliosis as common features of neurodegeneration [4].
Neuroinflammation, or, more specifically, the activation of the neuroimmune cells microglia and
astrocytes into proinflammatory states, is an effective endogenous defense that protects the central
nervous system (CNS) against microorganisms and injuries. It is usually a positive mechanism that
aims to eliminate threats and restore homeostasis [7]. However, prolonged neuroinflammatory events
can lead to a series of events that conclude with progressive neuronal damage that characterizes
many neurodegenerative disorders [8]. The glial cells, microglia and astrocytes, have a pro- and
anti-inflammatory role and are involved in different functions under physiological and disease
conditions, such as phagocytosis, steroid release, free radical reduction, and cellular repair [9].
Glial cells exert a proinflammatory action through the production of cytokines and reactive oxygen
species (ROS) that lead to synaptic dysfunction, loss of synapses, and neuronal death resulting
in CNS injury. Until now, most research has been focused on microglial cells as key actors of
neuroinflammation in neurodegeneration, but recently new scientific evidence has shown the important
contribution of astrocytes to the inflammation that characterizes neurodegenerative diseases [10–12].
Unfortunately, to date there are no pharmacological therapies able to slow down or stop the
progression of these devastating pathologies. For this reason, research is turning to the identification
of natural compounds with protective action against these diseases. Considering the important
role of neuroinflammation in the onset and development of neurodegenerative pathologies, natural
compounds with anti-inflammatory activity could be good candidates to develop effective therapeutic
strategies. Marine organisms represent a huge source of natural compounds, some of which have
different structural characteristics from those of terrestrial origin. Marine-derived natural compounds
could produce different pharmacological effects, like anti-diabetic [13], anti-inflammatory [14],
antioxidant [15], anticancer [16], and anti-obesity [17] activities, and open the way for the development
of new drugs [18]. Of note, seven marine-derived natural compounds have been approved for clinical
use [19].
Among marine organisms, algae are one of the most valuable resources of the sea. Epidemiological
studies comparing Japanese and Western diets show an association between algae consumption
and a lower incidence of chronic degenerative diseases [20]. Algae are appreciated sources of
important bioactive components such as antioxidants, proteins, vitamins, minerals, soluble dietary
fibers, polyunsaturated fatty acids, polysaccharides, sterols, carotenoids, tocopherols, terpenes,
phycobilins, phycocolloids, and phycocyanins [20]. Recently, Fernando et al. [21] summarized
the latest knowledge about the potential anti-inflammatory activity of marine algae derivatives,
evidencing their potential protective efficacy against neuroinflammation too. In particular, marine
algae have been shown to counteract neuroinflammation by acting at different cellular levels: inhibiting
pro-inflammatory enzymes such as COX-2 and iNOS [22], modulating MAPK pathways [23], and
NK-kB activation [24], among others. Currently there are no clinical trials on the effects of marine
algae against neuroinflammation but, given their important biological activities, as demonstrated by
in vitro and animal studies, we believe that they will be carried out in the near future. Moreover,
as anti-inflammatory drugs can trigger complications and important side effects [25,26], identifying
novel anti-inflammatory agents from marine algae could be a valid solution to overcome this problem.
In fact, anti-inflammatory natural compounds have been demonstrated to be safe thanks to their long
use in folk medicine [27].
This review highlights the key inflammatory processes involved in neurodegeneration and the
potential of marine algae and specific compounds from marine algae to counteract neuroinflammation
in the CNS. The most recent and relevant results on the promising anti-inflammatory activities of
marine algae related to neuroprotection have been selected.
2. Methods
A PubMed search was conducted. The combinations of terms that we used for this search
were “marine algae and neuroinflammation,” “marine algae and clinical studies,” “marine algae
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and inflammation,” “marine algae and toxicity,” and “marine algae.” We also combined the terms
marine algae and neuroinflammation with fucosterol, phlorotannins, astaxanthin, polysaccharides,
glycoprotein, chlorophyll, lutein, zeaxanthin, violaxanthin, neoxanthin, or β-carotene. No restrictions
were placed on the date of the articles or the language of publication. Studies with a clearly described
methodology were included.
3. Molecular Mechanisms of Neuroinflammation
Neuroinflammation is a defense process aimed to protect both the brain and the spinal cord from
tissue damage or pathogen invasion [8]. Generally, inflammatory processes involve numerous cellular
types and mediators with the aim of separating, via the formation of a glial scar, damaged tissue from
healthy tissue [28]. When an insult occurs at brain level, the immune response is mediated through
cross-talk between the CNS and the periphery. In fact, due to inflammation, blood-brain barrier (BBB)
permeability is increased and leucocytes can infiltrate into the CNS [9].
At the brain level, microglia, astrocytes, and oligodendrocytes constitute the neuroglial cells [29].
Microglia have been demonstrated to be derived from primitive macrophages [30] and are now
considered the resident immune system of the brain [31]. In non-activated conditions, microglia
contribute to brain homeostasis [32] by modulating neuronal survival and maintenance thanks to
the ability to release neurotrophic factors such as basic fibroblast growth factor and nerve growth
factor (NGF) [33]. Acting as immune cells, microglial cells are also responsible for the phagocytosis
of cell debris and contribute to the apoptosis of defective cells [34,35]. More recently, astrocytes,
which are known to be involved in CNS homeostasis by sustaining synapse plasticity, have also been
demonstrated to participate in protective signaling pathways such as those modulated by glycoprotein
gp130, which is crucial for glial cells’ survival [36], and by the transforming growth factor beta (TGFβ),
whose signaling has been shown to exert immunosuppressive effects and to inhibit nuclear factor κB
(NF-κB) nuclear translocation [37].
Beside their neuroprotective properties, the microglia supervise the brain environment by
modulating the immune functions in response to tissue damage, degeneration, and pathogen
infections [38]. Their activation can be triggered by different stimuli such as lipopolysaccharide
(LPS), a well-known toll-like receptor (TLRs) ligand [39], and they represent the first line of defense
against infections [40]. Microglia activation results in both morphological and biochemical changes:
cells lose their shape and begin to secrete inflammatory biomarkers such as cytokines, eicosanoids,
nitric oxide, and ROS [41,42].
Even though neuroinflammation does not usually trigger neurodegenerative diseases, it is directly
involved in neuronal dysfunctions and contributes to neuronal death and to neurodegenerative
disease progression [43]. In fact, diseases such as PD, AD, ALS, and MS, as well as ischemia and TBI,
are associated with chronic inflammation and long-lasting microglia activation [44]. Such chronic
inflammatory states result in an abnormal increased cytokine levels [45], the production of neurotoxic
mediators, and oxidative stress that triggers a pro-inflammatory cycle [46] and amplifies degenerative
processes such as abnormal protein deposition, mitochondrial dysfunction, and BBB permeability
impairment [44,47,48].
Chronic inflammation in neurodegenerative diseases is sustained by TLRs activation at the
glial level [49]. Among TLRs, TLR4 is the most expressed in microglia [50]; its activation has
been demonstrated to be responsible for chronic inflammation in AD, where Aβ-oligomers interact
with TLR4 and increase its expression [51,52], and in PD, where TLR4 protein expression is also
increased in both in vitro and in vivo model systems [53]. Moreover, TLR4 has been found to be
responsible for inflammation in spinal cord injury and stroke [54]. TLR4 activation triggers two
different downstream proinflammatory signaling pathways, leading to cytokine expression. Among
these pathways, the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathway, mammalian
target of rapamycin (mTOR) activation, and mitogen-activated protein kinases cascades (MAPKs)
are the main ones involved and lead to NF-κB activation [7,55,56]. Once activated, PI3K triggers
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Akt phosphorylation, which in turn activates mTOR. The mTOR pathway plays a pivotal role in the
regulation of NF-κB and inflammation [57]. NF-κB signaling is considered particularly important in
every neuroinflammation-related disease. After initial TLR4 activation, the sequence of events that
leads to the translocation of NF-κB to the nucleus includes the activation of the protein IκB kinase,
phosphorylation of the IκB inhibitory protein, and the consequent release of active NF-κB [58]. As a
dimer, NF-κB translocates to the nucleus, where it activates the transcription of its target genes such as
inducible nitric oxide synthase (iNOS), cyclooxygenase (COX2), tumor necrosis factor alpha (TNF-α),
interleukin (IL)-6, and IL-1β by binding to p65-responsive element [56]. During neuroinflammation,
NF-κB signaling is also stimulated in astrocytes [59], where its translocation to the nucleus and the
subsequent cytokines expression is triggered by IL-17-receptor [60] and lactosyl ceramide, a lipid
mediator produced by astrocytes [61]. Astrocytes’ contribution to neuroinflammation and neurotoxicity
has, thus, been demonstrated in models of different neurodegenerative diseases such as brain injury [62]
and spinal cord and nerve injury [63,64], where NF-κB inactivation resulted in positive outcomes.
MAPKs are proteins involved in the regulation of multiple cellular functions. In particular, they
are involved in the regulation of apoptosis, cell differentiation, and proliferation.
In activated microglia, increased signaling of p38 MAPK and c-Jun N-terminal kinases (JNK)
has been described [65]. These MAPKs induce, through the transcription factor activating protein-1
(AP-1), the transcription of proinflammatory genes such as COX2, TNF-α, and IL-6. The involvement
of p38 and JNK signaling in the LPS-activated MG6 microglial cell line has recently been confirmed,
showing that LPS treatment strongly induces phospho-p38/p38 and phospho-JNK/JNK ratio, the AP-1
translocation to the nucleus, iNOS protein expression, and NO production [65].
PI3K/Akt and MAPK are not the only pathways involved in neuroinflammation; the Janus
Kinase/Signal Transducers and Activators of Transcription (JAKs/STATs) signaling pathway represents
a further pathway able to trigger inflammation in the CNS [66]. Several cytokines trigger this pathway
by binding their specific receptors and promoting JAK kinase activity, both in microglia and astrocytes.
Once activated, JAK phosphorylates STAT, which dimerizes and translocates to the nucleus, where it
promotes the expression of cytokine-responsive genes. At least four JAK and seven STAT proteins have
been identified [67]. Specific combinations of JAKs and STATs are involved in the response to different
cytokines, allowing each cytokine to transduce its own message [66]. JAKs/STATs are involved in the
inflammatory response occurring in most neurodegenerative diseases. In MS, endoplasmic reticulum
stress induces astrocyte activation through JAK1/STAT3 signaling [68]. IL-6 and IFN-γ, two major
activators of JAKs/STATs signaling, are elevated in PD [69]; moreover, in primary microglial cell culture
it has been demonstrated that the inhibition of JAK 1/2 prevents the release of NO, TNF-α, and IL-1β
induced by α-synuclein treatment [70,71].
Besides classical inflammatory pathways, non-classical pathways, such as the Hippo pathway,
have been related to neuroinflammation and in particular to astrocyte activation [72]. In its typical
sequence of events, the Hippo pathway involves numerous kinases such as Mst 1/2, Sav1, and Last 1/2.
Last 1/2 phosphorylates and thus inactivates by proteasomal degradation or cytoplasmic retention, two
transcription factors: YAP and TAZ. When dephosphorylated YAP and TAZ migrate to the nucleus,
where they promote the expression of downstream genes [73]. YAP has been found to be highly
expressed in astrocytes and its deletion induced astrocytic activation in both cell cultures and in vivo
studies [72]. In astrocytes, IFNβ induced YAP activation, which, in turn, promoted the expression of
the suppressor of cytokine signaling 3 (SOCS3), a negative regulator of JAK-STAT. In fact, YAP(-/-)
astrocytes showed hyperactivation of the JAK-STAT pathway and astrocyte activation [72].
Neuroinflammation represents a crucial aspect of neurodegenerative disease progression.
Targeting neuroinflammatory pathways seems to be a promising strategy to counteract
neurodegenerative diseases. As different pathways are involved in the onset of neuroinflammation,
compounds with different molecular targets are the best candidates to fight this condition. On these
bases, beside drug development, the study of natural bioactive compounds, thanks to their varied and
complex structures, can help with the identification of effective anti-inflammatory agents.
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4. Marine Algae
Algae are photosynthetic eukaryotic organisms that present a complex and controversial taxonomy.
More than 20,000 species of algae have been identified, and on the basis of their size they are divided in
macroalgae (seaweeds) and microalgae. Macroalgae are multicellular marine plants, while microalgae
are small unicellular or simple multicellular species [74]. Marine macroalgae can be classified into three
classes according to their pigments: Brown (Phaeophyta) Green (Chlorophyta), and Red (Rhodophyta).
The pigments responsible for the algae’s color are: fucoxanthin (Phaephyta); chlorophyll a, b, lutein,
zeaxanthin violaxanthin neoxanthin, and β-carotene (Chlorophyta); phycobilliproteins and lutein,
zeaxanthin, and β-carotene (Rhodophyta). The classification of microalgae is extremely complex
considering the thousands of species present even in small areas of water.
Microalgae are classified into groups based on different characteristics: pigment composition,
morphological variations (rounded, oval, cylindrical, and fusiform cells), the presence of thorns,
cilia, flagella etc. In addition, they can be classified based on their sizes: picoplankton (0.2–2 µm),
nanoplankton (2–20 µm), and microplankton (20–200 µm). Recently, Corrêa et al., at the 16th IEEE
International Conference on Machine Learning and Applications in 2017, proposed a deep learning
technique to solve the problem by using as input low-resolution images [75].
Marine algae are composed of various substances: carbohydrates, lipids, proteins, amino acids,
vitamins, minerals, and secondary metabolites such as phytosterols and polyphenols [76]. The chemical
composition of macroalgae is considerably different between species and dependent on the season
(sunlight), habitat (salinity, depth in the sea), and environmental conditions.
4.1. Carbohydrates
Among the various components, carbohydrates are the most abundant constituents of marine
algae. Moreover, polysaccharides are usually the major component of red, green, and brown
algae [77,78], and monosaccharides and oligosaccharides are also present. The storage polysaccharide
is laminarin in brown algae and floridean in starch (more branched than amylopectin) in green
and red algae. Algae cell walls are characterized by the presence of uncommon polysaccharides
that can be sulfated, acetylated, etc. Marine algae carbohydrates are promising compounds in
various fields, such as food, pharmaceutical, and biomedical. Noteworthy therapeutic applications
are due to their antiviral, antibacterial, and antitumoral activities, antioxidant, antilipidemic, and
antiglycemic properties, and anti-inflammatory and immunomodulatory characteristics. In particular,
alginate-derived oligosaccharides inhibit neuroinflammation [79]. Laminarin (a polysaccharide
composed of (1,3)-β-d-glucan with β(1,6) branching), particularly abundant in Laminaria species, has
been demonstrated to possess antibacterial and chemopreventive activities, together with prebiotic
activity [80], important in modulating gut microbiota, which in turn can regulate neuroinflammation [81].
Algae polysaccharides have been also utilized in the cosmeceutical industries due to their chemical
and physical properties exhibiting potential benefits for skin [82].
Table 1 shows the different carbohydrates of brown, green, and red macroalgae.
The oligosaccharides derived from polysaccharides are also important. They are produced by chemical
or enzymatic hydrolysis and present numerous activities such as antioxidant, anti-inflammatory, and
anti-melanogenic [83–87]. Microalgae also produce polysaccharides, and release in particular sulfated
polysaccharides (carrageenan, ulvan, and fucoidan) [88–90]. Polysaccharides found in the cell wall vary
among microalgae genera and species. Microalgae present an advantage with respect to macroalgae
because they are easy to grow and culture and do not depend on the climate or season.
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Table 1. Carbohydrates in marine algae.
Carbohydrates Brown Macroalgae Red Macroalgae Green Macroalgae
monosaccharides
glucose, galactose,
xylose, fucose, uronic
acid, glucuronic acid
mannuronic acid,
guluronic acid
glucose, galactose,
mannose
glucose, mannose, xylose,
rhamnose, glucuronic acid,
uronic acid
polysaccharides
laminarin alginate,
fucoidan (sulphated),
cellulose, mannitol
carrageenans (sulfated),
agar (sulfated), floridean
starch, cellulose, lignin,
funoran
ulvan (sulfated), mannan,
galactans (sulfated),
xylans, floridean starch,
cellulose, lignin
To date the ability of algae-derived polysaccharides to counteract neuroinflammation has not yet
been fully explored.
4.2. Lipids
Algae contain different types of lipid phospholipids, non-polar glycerolipids, glycolipids, betaine
lipids, and some unusual lipids, e.g., sulfolipid (sulfoquinovosyldiacylglycerol) sterols [91].
Marine macroalgae have a low lipid content but the proportion of long-chained polyunsaturated
fatty acids (PUFA) is relatively high. In macroalgae, PUFAs are represented by omega-3 and omega-6
fatty acids. The content of PUFAs is generally higher in those living in cold water. Eicosapentaenoic
acid (EPA) is the principal fatty acid. PUFAs have health benefits: they regulate blood clotting and
blood pressure and develop functions of the brain and nervous systems [92,93]. They also decrease the
risk of many chronic diseases such as arthritis, diabetes, and obesity [94,95], and regulate the signaling
of microglia, mostly in the context of neuroinflammation and behavior [93].
Sterols. Among macroalgae, cholesterol is the most representative sterol in all the red algae;
fucosterol, which has anti-inflammatory activity, is the chief sterol in brown algae [96], and in green
algae the dominant sterol is isofucosterol clionasterol. Microalgae are characterized by the presence of
unusual dihydroxysterols, pavlovols, crinosterols, and stigmasterols. It has been proposed that sterols,
due to their ability to cross the blood-brain barrier, can prevent neuroinflammation [97,98], but there
are few reports of the neuroprotective activities of algae-derived phytosterols.
4.3. Proteins and Amino Acids
Macroalgae and microalgae have been used as a source of human nutrition for thousands of
years by some indigenous populations. This is due to their significant protein content, which is even
greater than some ground plant sources. Algae proteins are rich in aspartic and glutamic acid, the
latter contributing to the typical taste (umami). Green macroalgae, and especially red macroalgae,
have a higher protein content than brown macroalgae. Macroalgae also contain a number of bioactive
amino acids and peptides (e.g., taurine, carnosine, and glutathione and mycosporine-like) [99] that
have been demonstrated to exert antioxidant and antiapoptotic effects in the rat brain [100]. Lectins
are a group of glycoproteins isolated from algae [101] that present several properties including
anti-inflammatory [102,103] antibiotic, cytotoxic, mitogenic, antinociceptive, and anti-viral due to their
ability to bind to specific glycan structures [104]. Marine algae, with their high protein content, are
now considered a precious source of bioactive peptides, obtained after enzymatic digestion, with
considerable health potential. These biopeptides have been demonstrated to exhibit antioxidant,
anticancer, antihypertensive, antiatherosclerotic, and immunomodulatory activities [105]. In the future
it is desirable that research address the potential neuroprotective role of these biopeptides, elucidating
their mechanism of action.
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4.4. Phenols
Phenolic compounds are a class of chemical compounds characterized by hydroxyl groups directly
attached to aromatic hydrocarbon rings. The simplest is composed of one aromatic ring and is called
phenol. Phenolic compounds can be single phenols or polyphenols, depending on the number of
phenol units in the molecule.
Phenols are largely represented in all the organisms belonging to the Plant kingdom; however, the
phenols present in marine algae are different to those produced by terrestrial plants [104].
The best known polyphenols in marine algae are phloroglucinols and phlorotannins. Phlorotannins
can be classified into subclasses: eckols, fuhalols, fucophlorethols, phlorethols, fucols, and ishofuhalols.
The largest proportion of phenolic compounds is in green and red algae (bromophenols, phenolic
acids, and flavonoids). Phlorotannins are found only in marine brown algae [106,107].
Phenols and polyphenols from marine algae have attracted much attention for their anticancer,
antioxidant, antimicrobial, and anti-inflammatory activities [108]. To, date several mechanisms
behind microglial activation have been reported (see Section 3), and research is moving towards
the discovery of alternative anti-inflammatory compounds from natural renewable sources that
could potentially counteract neuroinflammation and, therefore, neuronal injury in neurodegenerative
diseases, characterized by complex and deeply related phenomena. Marine algae rich in phenols are
good candidates for potential application in the nutraceutical sector.
4.5. Isoprenoids
Carotenoids and terpenoids are two important classes of isoprenoids belonging to the marine
algae. Carotenoids contains eight isoprene units, while terpenoids contain five isoprene units.
The carotenoids that consist of only hydrocarbons are carotenes, while those with oxo, hydroxyl,
or epoxy groups are called xanthophylls. The most diffuse carotenoids in marine algae are: β-carotene,
fucoxanthin, astaxanthin, canthaxanthin, and lutein. Fucostantin is mostly present in brown algae and
in planktonic microalgae, while β-carotene is predominant in green microalgae [109,110].
The potential health-promoting effects of these carotenoids are: antioxidant activity,
anti-inflammatory effects, anticancer activity anti-obese effect, antidiabetic activity, hepatoprotective
effect, antiangiogenic effect, and cerebrovascular protective effect [111–113]. In particular, fucoxanthin
has been demonstrated to decrease inflammation and oxidative damage [114] and astaxanthin has
been demonstrated to decrease the expression of IL-6 in activated microglial cells [115], all factors
implicated in the pathogenesis of neurodegenerative diseases.
Brown macroalgae are considered one of the principal source of biologically and ecologically
relevant terpenoids, mainly diterpenes and meroditerpenes [116]. In Sargassum, meroterpenoids
prevail, in particular sargachromenol, which presents anti-inflammatory and neuroprotective effects.
Also, green algae are a source of terpenes, in particular the genus Caulerpa, which is represented by
about 60 species living in tropical and subtropical waters that biosynthesize acyclic and monocyclic
sesqui- and diterpenes [117] with neuroprotective activities.
5. Marine Algae and Neuroinflammation
As previously mentioned, activated microglia are a critical modulator of the neuroinflammation
process, triggering a self-feeding loop with the neighboring astrocytes through the release of
pro-inflammatory cytokines, including TNF-α and IL-1β [118]. In this context, a persistent and
unrestrained neuroinflammatory loop harms neuronal cells and can promote neurodegenerative
diseases [119]. Recent years have been characterized by a huge boost in nutritional research to
discover natural compounds with anti-inflammatory properties and potential neuroprotective capacity.
Marine algae have been part of a healthy diet in East Asia for centuries and represent a rich reservoir
of structurally different bioactive compounds with great potential for pharmaceutical applications.
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Increasingly, reports have shown the anti-inflammatory action of marine algae [120], as well as of their
major components such as phlorotannins and pigments [121–123].
The methanol extract of Ulva conglobata, a green alga consumed as a marine vegetable, has been
demonstrated to possess anti-inflammatory potential [22]. In particular, the extract was tested in
hippocampal neuronal HT22 cells and microglial BV2 cells. In HT22 cells, 40 and 50 µg/mL Ulva
conglobata extract was able to significantly restore cellular viability compared to glutamate-treated cells.
Moreover, Ulva conglobata extract effectively suppressed IFN-γ-induced microglial activation, and
50µg/mL inhibited NO release and reduced the expression of iNOS and COX-2 enzymes. Kim et al. [124]
found that the hexane fraction of brown seaweed Myagropsis myagroides ethanolic extract exhibits the
highest anti-inflammatory activity among different solvent fractions. In LPS-stimulated BV-2 cells,
25 µg/mL Myagropsis myagroides extract had the potential to revert the induction of pro-inflammatory
mediators such as NO, PGE2, and the cytokines IL-6 and TNF-α through the prevention of NF-κB
nuclear translocation and MAPKs phosphorylation. Surprisingly, they did not identify the active
compound responsible for these effects. Meanwhile, another report from the same authors suggested
that the anti-inflammatory activity of Myagropsis myagroides ethanolic extract in LPS-stimulated
BV-2 cells could be completely ascribed to the presence of sargachromenol [125]. A study assessed
the anti-neuroinflammatory capacity of three extracts obtained from Malaysian seaweed: Padina
australis, Sargassum polycystum, and Caulerpa racemosa [126]. All the extracts reduced the elevation of
inflammatory mediators like NO, TNF-α, IL-6, and IL-1β, with the brown seaweeds (Padina, Sargassum)
showing stronger inhibitory activity compared to the green seaweed (Caulerpa).
The so-called “cholinergic hypothesis” suggests a correlation between memory impairment in
AD and the reduction of neurotransmitter acetylcholine [127]. The preservation of acetylcholine
levels could be useful in view of a multitarget therapy. Fucosterol, a sterol mainly found in brown
algae including Padina australis, was isolated to investigate its cholinesterase and inflammatory
inhibitory properties [128]. It was observed that fucosterol inhibits acetylcholinesterase (AChE)
and butyrylcholinesterase (BChE), both responsible for acetylcholine hydrolysis, and significantly
prevents the production of pro-inflammatory mediators in LPS-induced C8-B4 microglial cells and in
Aβ-induced BV-2 microglial cells.
Ecklonia cava, an edible brown alga used for the production of food ingredients, animal feed, and
fertilizers, has been shown to possess anti-inflammatory activity [129,130].
Three of the major phlorotannins that can be found in Ecklonia cava eckol, dieckol, and 8,8’-bieckol,
were investigated for their protective effects against Aβ25-35-induced neuroinflammatory damage in
PC12 cells [130]. The results indicated that all phlorotannins tested possess antioxidant and protective
effects against Aβ damage, while dieckol has the strongest ability to combat apoptosis and Ca2+
overload and more effectively inhibits the increase of inflammatory markers and the protein levels
of p65, the best studied NF-κB subunit. Therefore, the neuroprotective property of dieckol with a
diphenyl ether linkage was greater than that of 8,8’-bieckol with a biaryl linkage, although these two
compounds are both dimers of eckol.
These data were further confirmed by Jung et al. [129], who isolated dieckol from Ecklonia cava
extract, reporting its potential as an anti-inflammatory agent by reducing the release and stimulation
of pro-inflammatory cytokines and enzymes together with an intracellular scavenging activity. Also, a
component from Ecklonia stolonifera, phlorofucofuroeckol B, was identified as a potent suppressor of
inflammation, inhibiting IκB-α/NF-κB and Akt/ERK/JNK pathways [23]. A study conducted by Kim
et al. [131] demonstrated, for the first time, that floridoside, a natural glycerol galactoside from the
red alga Laurencia undulata, possesses the potential to counteract the neuronal damage induced by
neuroinflammation in vitro, preventing ROS and NO overload due to iNOS and COX-2 overexpression.
Among algae pigments, fucoxanthin is one of the main carotenoids found in brown algae [132]. In an
Aβ42 -induced microglial activation model, fucoxanthin significantly reduced the rates of inflammatory
and oxidative damage, protecting DNA from oxidation and attenuating the increasing of inflammatory
enzymes [114]. Astaxanthin, a red carotenoid pigment, occurs naturally in plants and marine seaweeds,
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but also in shellfish and crustaceans [133]. It has been shown to possess a variety of pharmacological
effects, including anti-inflammatory and antioxidative activity [133–136].
Increasing evidence correlates a neuronal inflammation status with the development of
depression [137,138]. In a rat model of LPS-induced depressive-like behaviors, 80 mg/kg astaxanthin
had an antidepressant-like effect due to the restoration of LPS-induced alterations of brain inflammatory
markers (i.e., IL-1β, IL-6, and TNF-α), as well as iNOS, nNOS, and COX-2 expression via the modulation
of NF-κB activation [24].
In addition, Zhang et al. [139] found that astaxanthin administration could alleviate early brain
injury via suppressing the inflammation damage induced by subarachnoid hemorrhage. In particular,
75 mg/kg astaxanthin significantly reduced the elevated cortical levels of inflammatory mediators,
together with the degree of neutrophil infiltration.
A food supplement approved by the U.S. Food and Drug Administration (FDA), named
Aquamin, is a natural multi-mineral derived from the marine red seaweed Lithothamnion corallioides.
Aquamin was evaluated for its anti-neuroinflammatory potential, and in cortical glial-enriched
cells was able to suppress the release of LPS-induced TNF-α and IL-1β. Recently, several authors
suggested that anti-inflammatory and antioxidative agents could prevent the deposition of Aβ and the
subsequent brain damage [140,141]. Indeed, in the promoter of neuronal beta-secretase 1 (BACE1),
the enzyme involved in Aβ buildup, NF-κB DNA consensus sequences are present [142]. So, it
could be beneficial in treating AD to reduce microglia-mediated neuroinflammation and increase
microglia scavenger activity for toxic Aβ aggregates [143]. The ethanol extract of Nannochloropsis
oceanica demonstrated anti-inflammatory, antioxidative, and anti-amyloidogenesis activities in a
mouse model of LPS-induced AD [141]. The authors recently found that the main component of
Nannochloropsis oceanica is eicosapentaenoic acid (EPA), suggesting that it could be responsible for
the neuroprotective effects. The depolymerization of the polysaccharide alginate, found in many
marine brown algae, produces alginate-derived oligosaccharide with various biological activities
depending on the degradation method used [79]. The alginate-derived oligosaccharide produced by
enzymatic depolymerization showed anti-inflammatory activity by repressing the LPS and Aβ-induced
production of inflammatory cytokines and mediators in microglial cells. These effects have been
associated with the inactivation of the TLR4/NF-κB axis [79]. Interestingly, the interaction between
this oligosaccharide and TLR4 promotes the uptake of toxic Aβ aggregates. Regarding the possibility
of alginate-derived oligosaccharide crossing the BBB, the authors declared an average molecular
weight of 1500 Da and previous works demonstrated that oligosaccharides produced by enzymatic
depolymerization are able to pass through the BBB easily [25,144]. Differently, Bi et al. [13] synthesized
a seleno-polysaccharide from alginate-derived polymannuronate. Using in vitro/in vivo models of
microglia and astrocyte activation, the pre-treatment with seleno-polymannuronate reduced the
overgeneration of proinflammatory mediators, including NO, PGE2, TNF-α, IL-6, and IL-1β as well
as iNOS and COX-2, by suppressing the MAPK/NF-κB signaling pathway. Cui et al. [145] assessed
whether fucoidan, a class of fucose-enriched sulfated polysaccharides isolated from Laminaria japonica,
protects dopaminergic neurons from inflammation-mediated damage in a PD inflammatory rat model
induced by an intranigral injection of LPS. Fucoidan was able to improve behavioral deficits in
mice by protecting them from the loss of dopaminergic neurons. Other important anti-AD and
anti-inflammatory effects have been manifested by the glycoproteins purified from brown alga Undaria
pinnatifida [146]. Undaria pinnatifida displayed dose-responsive inhibition for AChE and BChE with
an IC50 of 63.56 and 99.03 µg/mL, respectively, and has been shown to inhibit BACE1, acting on the
neurotransmitter acetylcholine and on the formation and accumulation of Aβ aggregates. Moreover,
Undaria pinnatifida promotes cell survival and neurite extension, preventing inflammation status.
Epidemiological studies demonstrate a negative correlation between the use of non-steroidal
anti-inflammatory drugs (NSAIDs) and the incidence of inflammation in the nervous system, which in
turn participates in the development of neurodegenerative diseases [120]. The NSAIDs’ mechanism
of action involves the inhibition of the inflammatory mediator release. Marine algae can control the
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inflammatory process in microglia, suggesting their potential role as neuroprotective agents. Moreover,
the signaling pathways involved in the neuroprotective activity of algae are multiple. The complexity
of neurodegenerative diseases makes them difficult to counteract with single-target molecules. In
this context, marine algae, with their pleiotropic effects, have a great potential for application as
anti-neuroinflammatory agents. However, further studies are needed, along with clinical trials to
confirm marine algae’s anti-neuroinflammatory activity.
6. Conclusions
The wide range of biological and bioactive molecules found in marine algae represents a challenge
for researchers involved in the study of neuroinflammation/neurodegeneration processes. Marine
algae extracts and many marine algae constituents belonging to different chemical classes have been
demonstrated to exert preventive/protective effects against neuro-inflammation (Table 2). In particular,
they have been demonstrated to be effective in reducing inflammatory mediators like NO, TNF-α,
IL-6, and IL-1β, in downregulating inflammatory enzymes like iNOS and COX-2, and in modulating
the signaling pathways that lead to NF-κB activation. Moreover, most of the compounds isolated
from marine algae have also shown antioxidant activity. Oxidative stress represents a hallmark
of neuroinflammation and its counteraction could be a successful strategy in the prevention of
neurodegeneration. ROS production is strictly related to neuro-inflammation, and marine algae
compounds with both antioxidant and anti-inflammatory activities are good candidates to counteract
neurodegeneration thanks to their pleiotropic activity. A better knowledge of these molecules should
be associated with an implementation in the extraction and purification procedures in order to obtain
marine algae extracts with standardized concentrations to be applied in in vitro studies. In fact, the
choice of an appropriate extraction method can deeply influence the presence and concentration of
the bioactive compounds. Moreover, the ability of marine algae constituents to cross the blood-brain
barrier has not been investigated, which calls into question the possibility of developing them as
neuroprotective agents. Also, studies on potential adverse effects are lacking. Although still in
their infancy, studies on the anti-neuroinflammatory effects of marine algae compounds should be
corroborated by clinical trials. Currently there is a paucity of information reported in the literature,
which only contains studies on in vitro or animal models. Human studies could strengthen the choice of
marine algae products as potential nutraceutical compounds for the prevention of neuro-inflammation.
Table 2. Studies showing anti-neuroinflammatory activities of marine algae.
Marine Algae
Extract/Bioactive
Compound
Treatment Conc. Experimental Model Key Findings
Ulva conglobata
methanol extract 10-50 µg/mL
mouse hippocampal
HT-22 cells; mouse
microglial BV-2 cells
Restoration of cellular viability in
HT-22 cells; downregulation of
COX-2 and iNOS in BV-2 cells [22]
Exane fraction of
Myagropsis myagroides
ethanolic extract
5-25 µg/mL mouse microglialBV-2 cells
Decreased release of inflammatory
cytokines, inactivation of NF-κB
and reduced mRNA and protein
levels of iNOS and COX-2 [124]
Myagropsis myagroides
ethanolic extract 5–25 µg/mL
mouse microglial
BV-2 cells
Reduction in NO, PGE2, IL-6,
IL-1β and TNF-α release;
inhibition of ERKs-JNKs/NF-κB
axis [125]
Padina australis,
Sargassum polycystum
and Caulerpa racemosa
extracts
0.05–0.4 mg/mL mouse microglialC8-B4 cells
Decreased release of
pro-inflammatory mediators (NO,
PGE2, IL-6, IL-1β and TNF-α)
[126]
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Table 2. Cont.
Marine Algae
Extract/Bioactive
Compound
Treatment Conc. Experimental Model Key Findings
Fucosterol from
Padina australis 0.004–192 µM
mouse microglial
C8-B4 and BV-2 cells
Inhibition of AChE and BChE;
reduction in release of NO, PGE2,
IL-6, IL-1β and TNF-α in
LPS-stimulated C8-B4 cells;
prevented production of NO, IL-6
and TNF-α in Aβ42-stimulated
BV-2 cells [128]
Eckol, dieckol and
8,8’-bieckol from
Ecklonia cava
1–50 µM rat neuronal PC12cells
Antioxidant activity;
anti-apoptotic effects; decrease in
key inflammatory proteins
(COX-2, iNOS, IL-1β and TNF-α)
[130]
Dieckol from Ecklonia
cava 50–300 µg/mL
mouse microglial
BV-2 cells
Inhibition of LPS-induced iNOS
and COX-2 protein and mRNA
expression; suppression of p-38/
NF-κB pathway; ROS scavenging
activity [129]
Phlorofucofuroeckol
B from Ecklonia
stolonifera
10–40 µM mouse microglialBV-2 cells
Inhibition of IκB-α/NF-κB and
Akt/ERK/JNK pathways [23]
Floridoside from
Laurencia undulata 1–50 µM
mouse microglial
BV-2 cells
Inhibition of LPS-induced NO and
ROS production; downregulation
of COX-2 and iNOS mRNA and
protein levels by reducing p38 and
ERK phosphorylation [131]
Fucoxanthin 5–50 µM mouse microglialBV-2 cells
Attenuation of Aβ42-induced
cytokines release (NO, PGE2, IL-6,
IL-1β and TNF-α) and enzymes
upregulation (COX-2, iNOS) by
suppressing MAPKs
phosphorylation; protection from
H2O2-induced ROS release and
DNA damage by recovering
antioxidant enzymes [114]
Astaxanthin 20–80 mg/Kg male ICR mice
Reversed LPS-induced
depressive-like behaviors;
attenuation of cytokines level
(IL-6, IL-1β and TNF-α) and
antagonization of iNOS, nNOS
and COX-2 expression in the
hippocampus and prefrontal
cortex [24]
Astaxanthin 75 mg/Kg maleSprague-Dawley rats
Amelioration in cerebral edema,
blood-brain barrier disruption,
neurological dysfunction and
neuronal degeneration after the
induction of subarachnoid
hemorrhage; downregulation of
NF-κB activity, and intercellular
adhesion molecule-1, IL-1β and
TNF-α expression [139]
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Table 2. Cont.
Marine Algae
Extract/Bioactive
Compound
Treatment Conc. Experimental Model Key Findings
AquaminTM 0.05–2 mg/mL
cortical glial-enriched
cultures from
Sprague-Dawley rat
pups
Attenuation of LPS-induced IL-1β
and TNF-α secretion [147]
Nannochloropsis
oceanica ethanol
extract
50–100 mg/Kg male ICR mice
Decrease of ROS and
malondialdehyde levels;
improvement of LPS-induced
memory impairment; suppression
of Aβ42 generation by
downregulating APP and BACE1
expression [141]
Alginate-derived
oligosaccharide 50–500 µg/mL
mouse microglial
BV-2 cells
Inhibition of LPS/ Aβ42-induced
NO and PGE2 production, COX-2
and iNOS expression, and
cytokines secretion; attenuation of
TLR4 and NF-κB overexpression;
promotion of Aβ phagocytosis
[79]
Seleno-polymannuronate 0.5 mg/mL,0.8 mg/mL
primary microglia
and astrocytes from
BALB/c mouse pups;
female BALB/c mice
In LPS-activated primary cells,
attenuation of NF-κB and MAPK
signaling with the reduction of
NO, PGE2 production,
downregulation of COX-2 and
iNOS expression, and IL-6, IL-1β
and TNF-α secretion; decrease of
Iba1- and GFAP-positive cells in
the brain of a mouse model of
LPS-induced inflammation [13]
Fucoidan 7.5 mg/Kg, 15 mg/Kg;31.25–125 µg/mL
male
Sprague-Dawley rats;
primary microglia
from neonatal
Sprague–Dawley rats
Improvement of behavioral
deficits and prevention of
dopaminergic neuron loss;
inhibition of ROS and TNF-α
release [145]
Glycoprotein from
Undaria pinnatifida 5–45 µg/mL
primary
hippocampal cells
from embryonal
Sprague–Dawley rats
Inhibition of AChE, BChE and
BACE1; promotion of cell survival
and neurite extension [146]
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Abbreviations
AChE Acetylcholinesterase
AD Alzheimer’s disease
ALS Amyotrophic lateral sclerosis
AP-1 Activating protein 1
A- Amyloid beta
BACE1 Beta-secretase 1
BBB Blood-brain barrier
BChE Butyrylcholinesterase
CNS Central nervous system
COX-2 Cyclooxygenase-2
EPA Eicosapentaenoic acid
HD Huntington’s disease
IL Interleukin
iNOS Inducible nitric oxide synthase
JNK c-Jun N-terminal kinases
LPS Lipopolysaccharide
MAPKs Mitogen-activated protein kinases cascade
MS Multiple sclerosis
NF-κB Nuclear factor κB
NGF Nerve growth factor
nNOS Neuronal nitric oxide synthase
NO Nitric oxide
NSAIDs Non-steroidal anti-inflammatory drugs
PD Parkinson’s disease
PGE2 Prostaglandin E2
PUFA Polyunsaturated fatty acids
TBI Traumatic brain injury
TGFβ Transforming growth factor beta
TLRs Toll-like receptor
TNF-α Tumor necrosis factor alpha
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